When Are Missing Tissues a Protocol Deviation? As a prelude to answering this question, I would like to establish a common understanding of 3 related terms appearing in the good laboratory practices (GLPs). These are protocol amendment, protocol deviation, and unforeseen circumstance. In the Food and Drug Administration's (FDA's) view, the protocol is the master plan directing the conduct of the study. It was developed with considerable thought and effort, and it was specifically targeted to achieve the objectives of the study. Generally, the FDA does not like to see a large number of protocol amendments and deviations. They believe that this indicates a failure on the part of the study director to manage the study. All protocol amendments and deviations must be explained by the study director.
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Protocol amendments are systematic departures from the protocol that have a future effect. For example, if during a study it is decided to perform an interim sacrifice, this departure must be sanctioned in a protocol amendment. Protocol amendments are issued in writing by the study director. A protocol deviation is a one-time departure from the protocol that does not have a future effect. Examples would be taking weekly body weights on Monday rather than Tuesday, or harvesting only 24 tissues when the protocol required 36. Like protocol amendments, protocol deviations must be issued in writing by the study director.
Other one-time departures are considered to be &dquo;unforeseen circumstances&dquo; that occur during a study (see Section 58.33 of the GLPs). The FDA recognized that no complex endeavor such as the conduct of a pathology study could proceed absent error and they provided a means of dealing with that error. Study mistakes &dquo;that may affect the quality and integrity of the data are noted when they occur and corrective action is taken and documented.&dquo; Note that unforeseen circumstances need not require documentation by the study director. The documentation can be produced by the staff making the error. In my opinion, most glitches in a study are unforeseen circumstances and not protocol amendments or devia-
tions.
Examples are as follows: 1. A technician drops a rack of serum specimens intended for clinical pathology analysis, breaking all tubesunforeseen circumstance.
2. Not all small tissues are located at trimming-unforeseen circumstance.
3. Rat livers are not harvested-protocol deviation. 4. Additional skin specimens are taken-protocol amendment.
5. Additional clinical pathology is done-protocol amendment.
6. Special stains are requested-unforeseen circumstance.
7. Special stains are requested for all livers for all treatment groups-protocol amendment or unforeseen circumstances depending on the language in the protocol. Protocol deviations should be used sparingly because the GLPs provide other effective alternatives.
What Pathology Computerized Recording and
Reporting Systems Are Considered Validated in a GLP Sense?
Several months ago, I interviewed Dr. Charles Snipes, pharmacologist, with the Food and Drug Administration's (FDA's) Nonclinical Laboratory Studies Branch of the Center for Drug Evaluation and Research. Dr. Snipes has been FDA's lead person in investigating the use of computers in toxicology laboratories. He has inspected over 40 laboratories and, at each, he has left a Notice of Inspectional Observations (FDA-483). I asked him what the predominant finding was. He was unequivocal in his response-laboratories failed to have documentation adequate to assure that computer systems would operate in accord with design specifications. I don't think it would be productive for me to judge the good laboratory practices (GLP) compliance status of any of the contemporarily in-use pathology data systems. The FDA does not do this nor do they have a list of &dquo;GLP-adequate&dquo; systems. They evaluate each system as used in each laboratory and each laboratory's efforts in the qualification of that system. I think it is fair to say that any of the systems in use are probably in an adequate state of GLP compliance. Indeed, FDA has not taken an adverse action against a laboratory or a study because of faulty computer operation.
This does not mean that you should be complacent with your computer system. The FDA regulates pathology data systems as pieces of equipment that function in a laboratory. Accordingly, all of the equipment provisions of the GLPs apply to computers. In this regard, computers are to be of appropriate design and adequate capacity to function according to the protocol (demonstrated fitness for use), they are to be tested adequately, calibrated, standardized, inspected, cleaned, and maintained (adequate validation and acceptance testing), written records of equipment inspection, maintenance, testing, calibration, standardization, failure, and malfunction are to be kept (error logs and use documentation), their use is to be described in written standard operating procedures (SOPs) that are authorized by management, a historical file of SOPs is to be kept (version tracking), and laboratory personnel using computers are to be identified (authorized access procedures).
If you purchase a vendor-supplied system, FDA will expect that you have qualified the system as fit for use in your laboratory. They will expect you to have visited the vendor, interviewed development personnel, examined standard operating and quality assurance procedures, reviewed source code and test results, and evaluated other documentation to the effect that the system was adequately developed and validated. The results of your review should be summarized in a report with attachments that accepts the system for your laboratory. The In addition to the 2 editors, there are 75 contributors distributed through 43 chapters and grouped into 8 parts. Dr. John Weisburger states the purpose of the book quite clearly in his foreword: &dquo;The current monograph ... combines ... the essentials in toxicology logically extending into risk assessment.&dquo; At the outset, we need a definition of terms to that we can all play on an even field. For me, the term risk assessment covers the concepts of safety assessment and risk management. This is not a case of academic semantics, for there are approximately 25,000 federal employees involved in regulatory activities. Is safety assessment the same as risk assessment and the same as risk management? I do not think so. Safety assessment is essentially driven by biological methods and procedures. Risk assessment drivers are largely quantitative, mathematical approaches to the final decision of risk management. I alert the reader of this book review that it is reviewed through the distillate of 40 yr of experience as a toxicologic pathologist.
Who wrote the book? The senior editor is listed as a member of the California Environmental Protection Agency, Berkeley. As for the contributors, no graduate degrees nor the departments in which they currently work are listed. I must confess that the idea of checking the credentials of 77 scientists was not appealing. If a reference text is to be believable, then the reader needs to know if indeed the contributors are expert, authoritative sources. I never could understand why hard-earned graduate degrees and departmental designations for individuals are perceived as a potential &dquo;bias&dquo; for a book.
For each of the chapters, however, I checked the references for citations to the authors. They range from none to 6. It is difficult for me to accept as authoritative chapters by individuals with no references to their own work in the field about which they write. Maybe all 77 contributors are acknowledged experts, but how is the reader to know? Who is the audience for this book? The editors, in the preface, state, &dquo;This book is our first attempt to provide ... a textbook or reference book, all in one vol-ume, eliminating the need to go to a diversity of resources to get an overall view and perspective.&dquo; The chapter &dquo;Principles of Neurotoxicity&dquo; fills 13 pages, whereas the chapter &dquo;Biology of the Immune System and Immunotoxicity&dquo; occupies 9 pages. In a similar fashion, the chapter &dquo;Carcinogenesis: Basic Principles&dquo; is completed in 13 pages.
Unfortunately, there are serious disconnects between related chapters. The chapter &dquo;Carcinogenicity-Testing Methods&dquo; does not follow through on concepts stated in the chapter on carcinogenesis. Also, the chapter Biologically Based Cancer Modeling fills 22 pages and is a standalone without reference to the other chapters on cancer. Yes, there are some solid review chapters, which only makes you wish all the chapters were of equal quality. Can a single-volume, comprehensive reference book on toxicology and risk assessment be written? This is a daunting task that appears easy but is deceptively difficult. This is an admirable effort that does not quite make the grade for the intended audience. There are other monographs, reports, and books available that effectively compete for the same audience. As one firmly convinced that toxicology is a biological discipline, I am disappointed to see a &dquo;reference&dquo; text that does not incorporate the exciting age of molecular biology in a significant manner. Toxicologic pathology as a major player on the scientific team asked to determine whether or not a xenobiotic is safe for human exposure is not mentioned. This omission further highlights the lack of effective communication between toxicology and pathology. The contribution of pathology to understanding carcinogenesis is difficult to find in this book.
From the production standpoint, this book is printed on good-quality paper and bound well by a hard cover. Illustrations are clear and positioned close to where they are cited in the text. At a price of $195, though, I expect a Cadillac. Instead, I believe this is a Cadillac body with Chevrolet parts. Toxicologic pathologists may have a hard time driving this book to their expected destinations. BERNARD M. WAGNER, M.D.
Millburn Suite 208
Millburn, New Jersey 07041
